Platelet-Rich Fibrin with Minocycline versus Arestin in Non-surgical Periodontal Therapy: A Split-Mouth Randomised Controlled Clinical Trial

Periodontitis is a chronic inflammatory disease and while non-surgical periodontal therapy (NSPT) remains the first choice of treatment, its capability to completely resolve inflammation may be limited. Arestin® (1 mg minocycline microsphere) is an established adjunct, whereas platelet-rich fibrin (PRF) has recently emerged as a promising local drug-delivery scaffold. This split-mouth randomised controlled clinical trial compared the clinical efficacy of adjunctive minocycline delivered via conventional Arestin® versus incorporation within a PRF scaffold for the treatment of 4-6 mm periodontal pockets after NSPT.